Mutations in EGFR occur in 10% to 15% of all patients with NSCLC and predict responsiveness to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib (Iressa), and afatinib (Gilotrif). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.